These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 1603096)

  • 1. Analysis of antigenicity and immunogenicity of five different chemically defined constructs of a peptide.
    Marguerite M; Bossus M; Mazingue C; Wolowczuk I; Gras-Masse H; Tartar A; Capron A; Auriault C
    Mol Immunol; 1992 Jun; 29(6):793-800. PubMed ID: 1603096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antigenicity and immunogenicity of a multiple peptidic construction of the Schistosoma mansoni Sm-28 GST antigen in rat, mouse, and monkey. 1. Partial protection of Fischer rat after active immunization.
    Wolowczuk I; Auriault C; Bossus M; Boulanger D; Gras-Masse H; Mazingue C; Pierce RJ; Grezel D; Reid GD; Tartar A
    J Immunol; 1991 Mar; 146(6):1987-95. PubMed ID: 1900878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epitopic characterization and vaccinal potential of peptides derived from a major antigen of Schistosoma mansoni (Sm28 GST).
    Auriault C; Wolowczuk I; Gras-Masse H; Marguerite M; Boulanger D; Capron A; Tartar A
    Pept Res; 1991; 4(1):6-11. PubMed ID: 1724945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T and B epitope determination and analysis of multiple antigenic peptides for the Schistosoma mansoni experimental vaccine triose-phosphate isomerase.
    Reynolds SR; Dahl CE; Harn DA
    J Immunol; 1994 Jan; 152(1):193-200. PubMed ID: 7504709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of T and B cell epitopes of the Schistosoma mansoni P28 antigen in the rat model by using synthetic peptides.
    Auriault C; Gras-Masse H; Wolowczuk I; Pierce RJ; Balloul JM; Neyrinck JL; Drobecq H; Tartar A; Capron A
    J Immunol; 1988 Sep; 141(5):1687-94. PubMed ID: 2457624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and vaccine potential of dipeptidic multiple antigen peptides from Schistosoma mansoni glyceraldehyde 3-phosphate dehydrogenase.
    El Ridi R; Montash M; Tallima H
    Scand J Immunol; 2004 Oct; 60(4):392-402. PubMed ID: 15379864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in immunogenicity and vaccine potential of peptides from Schistosoma mansoni glyceraldehyde 3-phosphate dehydrogenase.
    Tallima H; Montash M; Veprek P; Velek J; Jezek J; El Ridi R
    Vaccine; 2003 Jul; 21(23):3290-300. PubMed ID: 12804860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the immune response elicited by a multiple antigen peptide (MAP) composed of two distinct protective antigens derived from the parasite Schistosoma mansoni.
    Ferru I; Georges B; Bossus M; Estaquier J; Delacre M; Harn DA; Tartar A; Capron A; Grassmasse H; Auriault C
    Parasite Immunol; 1997 Jan; 19(1):1-11. PubMed ID: 9121835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peptides and multiple antigen peptides from Schistosoma mansoni glyceraldehyde 3-phosphate dehydrogenase: preparation, immunogenicity and immunoprotective capacity in C57BL/6 mice.
    Veprek P; Jezek J; Velek J; Tallima H; Montash M; El Ridi R
    J Pept Sci; 2004 Jun; 10(6):350-62. PubMed ID: 15214440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T-cell responsiveness towards various synthetic peptides of the P28 antigen in rat and mouse models during Schistosoma mansoni infection.
    Wolowczuk I; Auriault C; Gras-Masse H; Mazingue C; Vendeville C; Tartar A; Capron A
    Int Arch Allergy Appl Immunol; 1990; 93(4):350-8. PubMed ID: 1713570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement of the T-cell response to a non immunogenic peptide by its tandem association with a highly efficient T-helper peptide.
    Rouaix F; Gras-Masse H; Mazingue C; Ridel PR; Diesis E; Marguerite M; Estaquier J; Capron A; Tartar A; Auriault C
    Immunopharmacology; 1994; 28(3):215-22. PubMed ID: 7531676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Schistosoma mansoni ex vivo lung-stage larvae excretory-secretory antigens as vaccine candidates against schistosomiasis.
    El Ridi R; Tallima H
    Vaccine; 2009 Jan; 27(5):666-73. PubMed ID: 19056448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity of multiple antigen peptides (MAP) containing T and B cell epitopes of the repeat region of the P. falciparum circumsporozoite protein.
    Munesinghe DY; Clavijo P; Calle MC; Nussenzweig RS; Nardin E
    Eur J Immunol; 1991 Dec; 21(12):3015-20. PubMed ID: 1721025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human IgG1 Responses to Surface Localised Schistosoma mansoni Ly6 Family Members Drop following Praziquantel Treatment.
    Chalmers IW; Fitzsimmons CM; Brown M; Pierrot C; Jones FM; Wawrzyniak JM; Fernandez-Fuentes N; Tukahebwa EM; Dunne DW; Khalife J; Hoffmann KF
    PLoS Negl Trop Dis; 2015; 9(7):e0003920. PubMed ID: 26147973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of synthetic peptides from the Sm31 antigen (cathepsin B) of the Schistosoma mansoni adult worms.
    Noya O; De Noya BA; Ballen DE; Bermúdez H; Bout D; Hoebeke J
    Parasite Immunol; 2001 Nov; 23(11):567-73. PubMed ID: 11703807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification, molecular cloning, and expression of a schistosome antigen displaying diagnostic potential.
    Newport GR; Hedstrom RC; Kallestad J; Tarr P; Klebanoff S; Agabian N
    Am J Trop Med Hyg; 1988 May; 38(3):540-6. PubMed ID: 3152782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rational selection of immunodominant and preserved epitope Sm043300e from Schistosoma mansoni and design of a chimeric molecule for biotechnological purposes.
    de Souza C; Lopes MD; De Oliveira FM; Passos MJF; Ferreira LCG; Faria BF; Villar JAFP; Junior MC; Taranto AG; Dos Santos LL; Fonseca CT; de Oliveira Lopes D
    Mol Immunol; 2018 Jan; 93():133-143. PubMed ID: 29175593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A mimotope peptide-based vaccine against Schistosoma mansoni: synthesis and characterization.
    Arnon R; Tarrab-Hazdai R; Steward M
    Immunology; 2000 Dec; 101(4):555-62. PubMed ID: 11122460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of cytotoxic T-cell activity by the protective antigen of Schistosoma mansoni Sm28GST or its derived C-terminal lipopeptide.
    Pancré V; Gras-Masse H; Delanoye A; Herno J; Capron A; Auriault C
    Scand J Immunol; 1996 Nov; 44(5):485-92. PubMed ID: 8947600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody responses to the fucosylated LacdiNAc glycan antigen in Schistosoma mansoni-infected mice and expression of the glycan among schistosomes.
    Nyame AK; Leppänen AM; Bogitsh BJ; Cummings RD
    Exp Parasitol; 2000 Dec; 96(4):202-12. PubMed ID: 11162373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.